(Q35760171)

10 August 2017

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system (English)

1 reference

systemic lupus erythematosus

10 August 2017

1 reference

1 reference

1 reference

1 reference

2

Kazuyoshi Saito

1 reference

10 August 2017

Mikiko Tokunaga

1

1 reference

10 August 2017

Daisuke Kawabata

3

1 reference

10 August 2017

Yoshitaka Imura

4

1 reference

10 August 2017

Takao Fujii

5

1 reference

10 August 2017

Shingo Nakayamada

6

1 reference

10 August 2017

Shizuyo Tsujimura

7

1 reference

10 August 2017

Masao Nawata

8

1 reference

10 August 2017

Shigeru Iwata

9

1 reference

10 August 2017

Taeko Azuma

10

1 reference

10 August 2017

Tsuneyo Mimori

11

1 reference

10 August 2017

Yoshiya Tanaka

12

1 reference

10 August 2017

language of work or name

English

0 references

publication date

15 November 2006

1 reference

Annals of the Rheumatic Diseases

10 August 2017

1 reference

10 August 2017

66

1 reference

10 August 2017

4

1 reference

10 August 2017

470-475

1 reference

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

Neuropsychiatric features of systemic lupus erythematosus

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

Cyclophosphamide: new approaches for systemic lupus erythematosus

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

Causes of death and prognostic factors in Thai patients with systemic lupus erythematosus.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

The 1982 revised criteria for the classification of systemic lupus erythematosus

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

Survival analysis of 306 European Spanish patients with systemic lupus erythematosus.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

CD40-CD40 ligand interaction in autoimmune disease

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

Pulse Cyclophosphamide for Severe Neuropsychiatric Lupus

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody).

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

An open study of B lymphocyte depletion in systemic lupus erythematosus

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

Elevated in vivo expression of the costimulatory molecule B7-BB1 (CD80) on antigen presenting cells from a patient with SLE

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1856059

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes

25 September 2018

1 reference

12 December 2020

Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab

1 reference

12 December 2020

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

12 December 2020

New therapies for systemic lupus erythematosus

1 reference

12 December 2020

Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy

1 reference

12 December 2020

Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement

1 reference

12 December 2020

[The expression and significance of costimulatory molecule in peripheral blood B lymphocytes in rheumatoid arthritis]

1 reference

12 December 2020

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

12 December 2020

Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus

1 reference

12 December 2020

Simultaneous determination of cerebrospinal fluid oligoclonal bands and the "gamma-protein index" by agarose electrophoresis and densitometry

1 reference

12 December 2020

Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate

1 reference

12 December 2020

Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients

1 reference

12 December 2020

Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.2006.057885

1 reference

10 August 2017

1 reference

10 August 2017

1 reference